Author Archives: Margarida Azevedo, MSc

ProMIS Moving into 2nd Phase of Work on Antibody Treatment for ALS

ProMIS Neurosciences announced that it is moving toward selecting antibodies — from the many identified in earlier work — that specifically target the toxic proteins that accumulate in the brains of amyotrophic lateral sclerosis (ALS) and Alzheimer’s patients, and that may work as therapies. Specifically for ALS, the identified antibodies target TDP43…

MDA Grants Include Research Projects for ALS and Other Diseases

The Muscular Dsytrophy Association (MDA) awarded 13 new grants totaling $2.6 million to find treatments for neuromuscular disorders, including amyotrophic lateral sclerosis (ALS). The 13 grants are divided into three types: Five grants were awarded to recognized, independent researchers; Five development grants were awarded to early-career scholars, and;…

ALS Association, Cytokinetics Renew Partnership in Fight Against ALS

The ALS Association and Cytokinetics will continue to collaborate in the fight against amyotrophic lateral sclerosis (ALS) through a series of initiatives and research efforts, the organizations recently announced. As part of this partnership, biopharmaceutical company Cytokinetics is renewing its sponsorship of nationally recognized ALS Association events, including the National…

European Agency Issues Negative Opinion on Marketing Authorization for Masitinib in ALS

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on the conditional marketing authorization of masitinib for the treatment of amyotrophic lateral sclerosis (ALS), the therapy’s maker, AB Science, recently announced in a press release. Masitinib is a tyrosine kinase inhibitor (TKI) being developed…